NCT07639021
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Recruiting
PHASE2Ages 18+InterventionalTreatmentNovo Nordisk A/S
~230 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:NNC0662-0419SemaglutideNNC0662-0419 PlaceboSemaglutide placebo
At a glance
Recruiting sites
24 of 25 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of gastrointestinal adverse events
Measured over From week 0 to week 39
Conditions
Where it's being run
25 sites across 18 statesFlorida3
Tennessee3
California2
Illinois2
Texas2
Alabama1
Indiana1
Kentucky1
Study leadership
- Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or above at the time of signing the informed consent.
Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening.
Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.
Exclusion
Known or suspected hypersensitivity to study intervention(s) or related products.
Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus.
What this trial measures
- Number of gastrointestinal adverse eventsFrom week 0 to week 39
Measured as number of events.